WASHINGTON (MedPage Today) — Reviewers from the Food and Drug Administration (FDA) questioned whether pixantrone (Pixuvri) effectively treats non-Hodgkin’s lymphoma (NHL) patients who haven’t responded to two prior chemotherapy treatments and said the drug has “substantial hematologic and cardiac toxicity.”
No Comments »
Filed under: General Health News
WASHINGTON (MedPage Today) — The FDA alerted healthcare professionals and consumers of a voluntary recall of a defibrillator that may fail during a resuscitation attempt.
No Comments »
Filed under: Pharmacy News
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, [...]
No Comments »
Filed under: Pharmacy News
Biodel, Inc. announced today that its chief executive officer, Dr. Sol Steiner, will present results from the company’s two Phase 3 studies with VIAject® ultra-rapid-acting recombinant human insulin in a platform presentation at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland, on Friday, February 12, 2010, at 1pm central [...]
No Comments »
Filed under: Pharmacy News
4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.
No Comments »
Filed under: Pharmacy News
At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company’s lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab’s activity in B-cell non-Hodgkin’s lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.
No Comments »
Filed under: Pharmacy News
A clinical trial of Exsulin, an innovative new treatment that targets the underlying cause of type 1 diabetes, has begun at the McGill University Health Centre (MUHC). Under the direction of Dr. George Tsoukas of the MUHC and the McGill University Faculty of Medicine, the study will assess the effectiveness of Exsulin.
No Comments »
Filed under: Pharmacy News
QRxPharma Limited announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.
No Comments »
Filed under: Pharmacy News
Ten GOP Health Ideas For Obama The Wall Street JournalThe best ideas out there are not those that were passed by the House and Senate last year, which consist of more spending, more regulations and more bureaucracy. If the president is serious about building a system that delivers more quality choices at lower cost for [...]
No Comments »
Filed under: Pharmacy News
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone…
No Comments »
Filed under: Pharmacy News
